<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03119883</url>
  </required_header>
  <id_info>
    <org_study_id>17-003133</org_study_id>
    <nct_id>NCT03119883</nct_id>
  </id_info>
  <brief_title>Assessing Glutamine Metabolism in MGUS and Myeloma</brief_title>
  <official_title>Dysregulation of Glutamine Metabolism in the Pathogenesis of Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The utilization of glutamine by the bone marrow plasma cells in MGUS and MM will be compared&#xD;
      between each other after infusion of 13-carbon labelled glutamine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma (MM) is always preceded by a pre-malignant asymptomatic phase, monoclonal&#xD;
      gammopathy of undetermined significance (MGUS). Given the incurable nature of MM it is vital&#xD;
      to study the development of MM from MGUS to help in identifying early diagnostic and&#xD;
      treatment opportunities. This project aims to determine if glutamine metabolism in plasma&#xD;
      cells is vital for their survival and whether it is associated with the progression of MGUS&#xD;
      to MM. It will involve the utilization of stable isotope resolved metabolomics methods to&#xD;
      evaluate the utilization of glutamine by the bone marrow plasma cells in MGUS compared to MM.&#xD;
      Patients with MGUS and MM will undergo bone marrow aspirations after being infused with&#xD;
      13-carbon labelled glutamine. The subsequent bone marrow plasma cells obtained from these&#xD;
      aspirates will undergo GC-MS assessments of the TCA cycle isotopomers. This will help&#xD;
      determine the differences in the utilization of glutamine by the bone marrow plasma cells&#xD;
      between MGUS and MM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent enrichment of 13-Carbon in the TCA cycle intermediates within bone marrow plasma cells from patients with MGUS and Multiple Myeloma.</measure>
    <time_frame>1 day</time_frame>
    <description>Compare the glutamine anaplerosis activity in bone marrow clonal plasma cells between patients with MGUS and Multiple Myeloma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent enrichment of 13-Carbon in the TCA cycle intermediates within bone marrow plasma from patients with MGUS and Multiple Myeloma.</measure>
    <time_frame>1 day</time_frame>
    <description>Compare the glutamine anaplerosis activity in the plasma cells by assessing the bone marrow plasma between patients with MGUS and Multiple Myeloma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent enrichment of 13-Carbon in the TCA cycle intermediates within the peripheral blood plasma from patients with MGUS and Multiple Myeloma.</measure>
    <time_frame>1 day</time_frame>
    <description>Compare the peripheral blood enrichment of 13-carbon in the TCA cycle intermediates from patients with MGUS and Multiple Myeloma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Myeloma</condition>
  <condition>MGUS</condition>
  <arm_group>
    <arm_group_label>MGUS group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MGUS patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Myeloma group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Multiple Myeloma patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infusion of 13-Carbon labeled Glutamine</intervention_name>
    <description>Intravenous infusion of 13-Carbon labeled glutamine followed by bone marrow aspiration</description>
    <arm_group_label>MGUS group</arm_group_label>
    <arm_group_label>Multiple Myeloma group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IMWG criteria for the diagnosis of either MGUS or MM5&#xD;
&#xD;
          -  Presence of measurable disease defined by an M-spike of &gt;1 g/dL and/or involved serum&#xD;
             free immunoglobulin light chain &gt;10 mg/dL&#xD;
&#xD;
        For MGUS cohort only:&#xD;
&#xD;
          -  At least 5 to &lt;10% cPCs in the prior BM aspirate&#xD;
&#xD;
          -  Not received any plasma cell directed therapy&#xD;
&#xD;
        For MM cohort&#xD;
&#xD;
          -  At least &gt;10% cPCs in recent BM aspirate&#xD;
&#xD;
          -  Newly diagnosed MM without receiving any plasma cell directed therapy OR Relapsed MM&#xD;
             without having received salvage chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For both MGUS and MM cohorts&#xD;
&#xD;
          -  Unable to provide consent&#xD;
&#xD;
          -  ECOG PS &gt;1&#xD;
&#xD;
          -  Hemoglobin &lt;10 g/dL&#xD;
&#xD;
          -  GFR &lt;50 ml/min&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Abnormal liver function tests&#xD;
&#xD;
          -  Abnormal bleeding history or coagulation profile (INR &gt;1.5)&#xD;
&#xD;
          -  Prior history of adverse events with conscious sedation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wilson I Gonsalves, MD</last_name>
    <phone>507-284-2511</phone>
    <email>gonsalves.wilson@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Colleen Irlbeck</last_name>
    <phone>507-284-2511</phone>
    <email>irlbeck.colleen@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilson Gonsalves</last_name>
      <phone>507-284-2511</phone>
      <email>gonsalves.wilson@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2017</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Wilson I. Gonsalves, M.D.</investigator_full_name>
    <investigator_title>Senior Associate Consultant</investigator_title>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Glutamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

